Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

EASD 2013

- PMLiVE

Novo Nordisk’s Wegovy approved by FDA as oral medication for weight management

Those taking the 25mg pill lost a similar amount of weight as those using injectable Wegovy 2.4mg

- PMLiVE

Lilly and Indiana University collaborate to expand clinical trial access

The five-year agreement includes a focus on R&D for Alzheimer’s disease

- PMLiVE

Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

While the trials did not meet their primary endpoints, they highlighted important biomarker findings

- PMLiVE

Vandria announces positive phase 1 data for Alzheimer’s treatment

Trial data showed that VNA-318 has the ability to penetrate the brain

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

- PMLiVE

Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

Inizio

- PMLiVE

Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

- PMLiVE

Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

- PMLiVE

Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

- PMLiVE

Novo Nordisk agrees to lower certain drug prices in the US

The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

- PMLiVE

Novo Nordisk reports sales growth in 2025 as R&D pipeline advances

Growth driven by increased sales in diabetes and obesity markets

- PMLiVE

Lilly’s early Alzheimer’s disease treatment approved in the EU

Marketing authorisation follows positive late-stage trial results

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links